2025年国谈在京开启，谈判速度比往年更快了

Core Viewpoint - The 2025 National Medical Insurance Negotiation has commenced, with significant price reductions expected, exceeding initial estimates by 40%-50% for many companies [1][6]. Group 1: Negotiation Overview - The negotiation began on October 30, 2023, and is expected to last 4-5 days, starting with basic medical insurance directory negotiations followed by commercial insurance innovative drug price discussions [2][3]. - This marks the 8th adjustment of the medical insurance directory since the establishment of the National Medical Insurance Bureau, involving a five-step process: preparation, application, expert review, negotiation, and result announcement [5]. Group 2: Participants and Dynamics - Numerous representatives from major pharmaceutical companies, including domestic and international firms like Shiyao Group, Green Leaf Pharmaceutical, and Pfizer, participated in the negotiations [9]. - The pace of negotiations appeared faster than in previous years, with representatives exiting the venue more frequently without prolonged discussions [9]. Group 3: Key Changes in Negotiation Structure - A significant change this year is the introduction of a commercial insurance innovative drug directory, aimed at integrating basic medical insurance and commercial insurance, enhancing the multi-tiered medication security system [13][14]. - There are 79 drugs that applied for both the basic medical insurance directory and the commercial insurance innovative drug directory, with a sequential negotiation process established [16]. Group 4: Future Implications - The commercial insurance innovative drug directory may serve as a transitional model for innovative drug payments, allowing drugs to first enter the commercial directory before potentially being included in the basic medical insurance directory after gathering real-world data [17].